Zhang Guohua, Yang Guang, Deng Yan, Zhao Xiangling, Yang Yingbao, Rao Jinjun, Wang Wenya, Liu Xin, He Jian, Lv Lin
School of Traditional Chinese Medicine, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, P. R. China.
School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, P. R. China.
BMC Complement Altern Med. 2016 Feb 6;16:56. doi: 10.1186/s12906-016-1030-3.
Xue-Fu-Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin (TMGTY) and Wen-Dan decoction (WDD) are Chinese herbal formulas used to treat hypertension and cardiovascular diseases in traditional Chinese medicine (TCM). The goal of our study is to determine if XFZYD, TMGTY or WDD treatment ameliorated myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to identify the mechanisms underlying any beneficial effects observed during the courses of the investigation.
Forty-five 12-week-old male spontaneously hypertensive rats and five age-matched male Wistar-Kyoto control rats were studied for 16 weeks. Each day 6 g∙kg(-1) or 12 g∙kg(-1) of XFZYD, TMGTY or WDD was orally administered at the indicated dose, and the systolic blood pressure (SBP) of all rats was measured using the tail-cuff method. Collagen levels were measured via hydroxyproline content assays and histological examination. Transforming growth factor beta-1 (TGF-β1) protein levels were determined via immunhistochemical and Western blot analysis. TGF-β1 mRNA levels were assessed using real-time reverse transcription polymerase chain reaction.
Systolic blood pressure was unaffected, but collagen and TGF-β1 levels in SHRs treated with captopril and XFZYD (12 g∙kg(-1)) were significantly reduced when compared with untreated control SHRs. Administration of 12 g∙kg(-1) XFZYD increased myocardial cell protection and decreased TGF-β1 mRNA and protein expression when compared with the other SHR treatment groups.
XFZYD treatment demonstrated a superior ability to reverse myocardial fibrosis when compared with WDD or TMGTY treatment in SHRs. XFZYD also decreased TGF-β1 mRNA and protein expression, suggesting that the TGF-β1 signaling pathway plays a role in the therapeutic effects of XFZYD treatment.
血府逐瘀汤（XFZYD）、天麻钩藤饮（TMGTY）和温胆汤（WDD）是用于治疗高血压和心血管疾病的中药方剂。我们研究的目的是确定XFZYD、TMGTY或WDD治疗是否能改善自发性高血压大鼠（SHRs）的心肌纤维化，并确定在研究过程中观察到的任何有益作用的潜在机制。
对45只12周龄雄性自发性高血压大鼠和5只年龄匹配的雄性Wistar-Kyoto对照大鼠进行了16周的研究。每天按指定剂量口服6 g∙kg(-1)或12 g∙kg(-1)的XFZYD、TMGTY或WDD，并使用尾套法测量所有大鼠的收缩压（SBP）。通过羟脯氨酸含量测定和组织学检查测量胶原蛋白水平。通过免疫组织化学和蛋白质印迹分析确定转化生长因子β1（TGF-β1）蛋白水平。使用实时逆转录聚合酶链反应评估TGF-β1 mRNA水平。
收缩压未受影响，但与未治疗的对照SHRs相比，用卡托普利和XFZYD（12 g∙kg(-1)）治疗的SHRs中的胶原蛋白和TGF-β1水平显著降低。与其他SHR治疗组相比，给予12 g∙kg(-1) XFZYD可增强心肌细胞保护并降低TGF-β1 mRNA和蛋白表达。
与WDD或TMGTY治疗相比，XFZYD治疗在SHRs中显示出更强的逆转心肌纤维化的能力。XFZYD还降低了TGF-β1 mRNA和蛋白表达，表明TGF-β1信号通路在XFZYD治疗的疗效中起作用。
